key: cord-0816435-a3x0uyoj
authors: Dell’Edera, Alessandro; Borghesan, Franco; Favero, Elisabetta; Rattazzi, Marcello; Scarpa, Riccardo; Tartaglia, Leonardo; Agostini, Carlo; Cinetto, Francesco
title: Venom Immunotherapy during COVID-19 pandemic: Experience from a University Allergy Center in Northern Italy
date: 2020-11-13
journal: World Allergy Organ J
DOI: 10.1016/j.waojou.2020.100489
sha: 4d885bc8acbeb1fa67b93e05461df88ea1307d28
doc_id: 816435
cord_uid: a3x0uyoj

During the ongoing pandemic of Coronavirus Disease 2019 (COVID-19) allergic patients need to continue their constant and proper treatment, including allergen-specific immunotherapy. These patients are expected to be at a higher risk for exacerbation of lung inflammation during viral infection. We investigated the putative interplay existing between allergen-specific immunotherapy and COVID-19 infection in Hymenoptera venom–allergic population. We evaluated the frequency and severity of COVID-19 infection in a cohort of 211 subjects referring to our Center for the regular administration of venom immunotherapy (VIT). Our result showed that the median age of our cohort is similar to the one that in our region has been associated with a high incidence of COVID-19 infection, increased hospitalization and mortality rates. We reported only an isolated positivity of COVID-19 in the overall group, whereas none suffered from upper airway symptoms associated with COVID-19 (fever, cough, dyspnoea, sore throat, anosmia and/or ageusia). Even though the demographic characteristics pose a substantial risk for such a population, we suggest that a regular administration of VIT may help to the development of an immunological milieu able to down modulate the Th1/Th17 environment that has been linked to inflammatory manifestations of COVID-19. To the best of our knowledge, this is the first description of the incidence of COVID-19 infection in Hymenoptera venom allergic patients treated with VIT, suggesting indirectly that venom immune tolerance-inducing treatment may be capable of reducing the aberrant inflammatory response induced by the virus in this specific population.

The authors declare that there is no conflict of interest. Acknowledgements: None.

No funding to declare.

Authors provide formal written Consent to Publish.

Approval was obtained from the local ethics committee.

The data that support the findings of this study are available on request from the corresponding author, A.D. The data are not publicly available due to their containing information that could compromise the privacy of research participants. patients are in mono-therapy with angiotensin-converting enzyme inhibitors (ACE-i).

5 subjects work as health care professionals.

Covid-19 -Navigating the Uncharted

Allergic respiratory disease care in the 144 COVID-19 era: a EUFOREA statement

Mechanisms of allergen-specific 146 immunotherapy and novel ways for vaccine development

Perspectives in allergen 148 immunotherapy: 2019 and beyond

Il-10 producing T and B cells in 150 allergy

Mechanisms of allergen-specific immunotherapy: Multiple suppressor 152 factors at work in immune tolerance to allergens